Synapse - Isabelle Riviere

Results (35)

Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies

Meeting Abstract

Shahid, S.; Flynn, G. C.; Mauguen, A.; Bieler, J.; Prockop, S. E.; Scaradavou, A.; Boelens, J. J.; Sauter, C. S.; Perales, M. A.; Giralt, S. A.; more...
Blood (2023)

Fulltext@MSK | Save

A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2

Meeting Abstract

Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
Blood (2023)

Fulltext@MSK | Save

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results

Journal Article

Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
Nature Medicine (2023)

Fulltext@MSK | Save

GPRC5D-targeted CAR T cells for myeloma

Journal Article

Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
New England Journal of Medicine (2022)

Fulltext@MSK | Save

Discovery proteomics for analytes to predict cytokine release syndrome on day of infusion of chimeric antigen receptor (CAR) T cells

Meeting Abstract

Lakkaraja, M.; Hosszu, K.; Mcavoy, D.; Mauguen, A.; Purdon, T. J.; Auchincloss, T.; Klein, E.; Khakoo, Y.; Santomasso, B.; Senechal, B.; more...
Cytotherapy (2022)

Fulltext@MSK | Save

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Journal Article

Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K. V.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P.; more...
Nature Medicine (2022)

Fulltext@MSK | Save

The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies

Meeting Abstract

Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
Blood (2021)

Fulltext@MSK | Save

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
Blood (2021)

Fulltext@MSK | Save

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab